Academic Neurology and the COVID-19 Pandemic
Resilience, Hope, and Solutions
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 16, 2022
- Accepted in final form September 28, 2022
- First Published December 1, 2022.
Article Versions
- Previous version (December 1, 2022 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Nina F. Schor, MD, PhD,
- Merit E. Cudkowicz, MD and
- Brenda Banwell, MD
- Nina F. Schor, MD, PhD,
None
NONE
None
MedLink Neurology, Pediatric Neurology, Journal of Child Neurology(member of editorial boards of these journals; 2000-present)
NONE
Nelson's Textbook of Pediatrics, Elsevier, 2011 and 2013.Swaiman's Pediatric Neurology: Principles and Practice, Elsevier, 2011, 2016.
NONE
NONE
NONE
NONE
NONE
NONE
I was an employee of the National Institute of Neurological Disorders and Stroke at the time of performance of this work. I have been and remain an employee of the NIH (2018-present).
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Merit E. Cudkowicz, MD and
Locust Walk
NONE
None
Neurotherapeutics editorial boardJAMA Neurology editorial boardAnnals of Neurology Editorial Board
Metabolomics in ALS - patentMIR 155 inhibitor - patent
UptoDate MND chapter
NONE
Neurosense, Biogen, Regeneron, Transposon, Locustwalk, Arrowhead, Praxis, Vector, Servier, Eledon, Cytokinetics
NONE
NONE
NONE
Grants from UCB, Biohaven, Clene Nanomedicines, Prilenia, Seelos, Calico, Revalesio, all for platform trial
NONE
NINDS - U01 NeuroNEXT
Muscular dystrophy association, als association, als finding a cure foundation, ALS One
Praxis Precision medicine, options, board member
NONE
NONE
NONE
NONE
NONE
- Brenda Banwell, MD
Scientific Advisory Board, Biogen-IDEC, Sanofi, Eli Lilly,Novartis, UCB, Roche.
NONE
Novartis, Roche, UCB
I serve on the Editorial Board for Neurology. I receive no financial remuneration.
NONE
NONE
NONE
I have served as a consultant to Novartis, Roche, Sanofi, and UCB.
I have spoken at an event supported by the Consortium of MS Centers, the Corpus, and Medscape more than 12 months ago
NONE
NONE
NONE
NONE
NONE
Multiple Sclerosis Society of CanadaMultiple Sclerosis Scientific Research FoundationNational Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
NONE
- From the National Institutes of Health (N.F.S.), Bethesda, MD; Massachusetts General Hospital (M.E.C.), Harvard Medical School, Boston, MA; Children's Hospital of Philadelphia (B.B), Perelman School of Medicine, University of Pennsylvania, PA.
- Correspondence
Dr. Banwell banwellb{at}email.chop.edu
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.